Galectin Therapeutics reported $27.29M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Gilead Sciences USD 16.55B 4.02B Sep/2026
Immunic USD 135.09M 22.75M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Merck USD 38.94B 2.26B Sep/2026